Published in J Neurooncol on September 10, 2010
Dual targeting strategies with bispecific antibodies. MAbs (2012) 2.13
Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin J Cancer (2011) 1.45
Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol Cancer Ther (2011) 0.91
Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol (2013) 0.90
A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells. MAbs (2014) 0.84
A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma. Target Oncol (2013) 0.83
Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development. Toxins (Basel) (2015) 0.83
Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors. Int J Cancer (2013) 0.78
Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. Nat Rev Clin Oncol (2017) 0.78
Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. Anticancer Agents Med Chem (2011) 0.77
Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma. Oral Oncol (2012) 0.77
Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR. Mol Cancer Ther (2017) 0.77
Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges. Biomed Res Int (2017) 0.75
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res (2006) 3.31
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res (2007) 3.30
Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med (1997) 2.76
Recombinant toxins as novel therapeutic agents. Annu Rev Biochem (1992) 2.05
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol (2009) 1.86
Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res (2009) 1.84
Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice. Leuk Res (2005) 1.68
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A (2008) 1.66
Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res (2003) 1.65
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol (2006) 1.42
Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res (1998) 1.38
Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci U S A (2006) 1.30
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery (2007) 1.27
A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res (2005) 1.26
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res (1995) 1.19
Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle (2005) 1.19
Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J (1995) 1.19
Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat (2006) 1.11
Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood (2003) 1.10
Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv Drug Deliv Rev (2009) 1.07
Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res (2007) 1.07
A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer. Clin Cancer Res (2007) 1.02
Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies. Science (1983) 0.99
The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem (2009) 0.99
A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res (2009) 0.97
Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer (2009) 0.96
The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice. Transplantation (1994) 0.95
Targeted tumor therapies at a glance. Curr Drug Targets (2009) 0.90
Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst (2002) 0.90
Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme. Neurosurg Focus (2006) 0.87
Update on diagnostic practice: tumors of the nervous system. Arch Pathol Lab Med (2009) 0.86
Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. J Neurooncol (2009) 0.85
Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor. J Neurooncol (2000) 0.83
Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice. Int J Cancer (2007) 0.82
Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur J Cancer (1995) 0.81
A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature (2012) 11.68
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet (2002) 4.06
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
Modeling recent human evolution in mice by expression of a selected EDAR variant. Cell (2013) 2.17
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res (2011) 2.06
Electron-pinned defect-dipoles for high-performance colossal permittivity materials. Nat Mater (2013) 2.05
Structural genomics: a pipeline for providing structures for the biologist. Protein Sci (2002) 1.91
Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res (2009) 1.84
Impaired integrin-dependent function in Wiskott-Aldrich syndrome protein-deficient murine and human neutrophils. Immunity (2006) 1.79
The role of surface oxygen in the growth of large single-crystal graphene on copper. Science (2013) 1.79
Genetic variations in Tibetan populations and high-altitude adaptation at the Himalayas. Mol Biol Evol (2010) 1.77
Estrogen signaling in livers of male mice with hepatocellular carcinoma induced by exposure to arsenic in utero. J Natl Cancer Inst (2004) 1.73
Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice. Leuk Res (2005) 1.68
Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev (2008) 1.65
MOCAT: a metagenomics assembly and gene prediction toolkit. PLoS One (2012) 1.64
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther (2010) 1.59
Vertically aligned carbon nanofiber arrays: an advance toward electrical-neural interfaces. Small (2006) 1.57
Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther (2010) 1.57
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiol Drug Saf (2011) 1.50
De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res (2009) 1.49
TST, as a polysomnographic variable, is superior to the apnea hypopnea index for evaluating intermittent hypoxia in severe obstructive sleep apnea. Eur Arch Otorhinolaryngol (2014) 1.42
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med (2011) 1.42
1,1,3-Trimethyl-3-phenyl-indane. Acta Crystallogr Sect E Struct Rep Online (2008) 1.41
Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood (2009) 1.35
Identification of the proliferation/differentiation switch in the cellular network of multicellular organisms. PLoS Comput Biol (2006) 1.32
Classification of inflammation activity in ulcerative colitis by confocal laser endomicroscopy. Am J Gastroenterol (2009) 1.30
Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab (2012) 1.30
Human BAMBI cooperates with Smad7 to inhibit transforming growth factor-beta signaling. J Biol Chem (2009) 1.29
Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis (2002) 1.28
Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res (2010) 1.28
Genome-wide mapping of SMAD target genes reveals the role of BMP signaling in embryonic stem cell fate determination. Genome Res (2009) 1.27
Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy. J Neurooncol (2006) 1.27
A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res (2005) 1.26
Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res (2013) 1.26
Determining the folding and unfolding rate constants of nucleic acids by biosensor. Application to telomere G-quadruplex. J Am Chem Soc (2004) 1.25
Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg (2007) 1.24
Genetic evidence of paleolithic colonization and neolithic expansion of modern humans on the tibetan plateau. Mol Biol Evol (2013) 1.22
Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett (2010) 1.22
Characterizing IgG4-related disease with ¹⁸F-FDG PET/CT: a prospective cohort study. Eur J Nucl Med Mol Imaging (2014) 1.21
Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos (2012) 1.19
A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjögren's syndrome at 7q11.23. Nat Genet (2013) 1.19
Unilateral versus bilateral balloon kyphoplasty in the treatment of osteoporotic vertebral compression fractures. Orthopedics (2014) 1.19
In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother (2007) 1.18
GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. Cancer Res (2013) 1.16
Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther (2012) 1.16
Wafer-scale fabrication of patterned carbon nanofiber nanoelectrode arrays: a route for development of multiplexed, ultrasensitive disposable biosensors. Biosens Bioelectron (2009) 1.16
Identification of a Tibetan-specific mutation in the hypoxic gene EGLN1 and its contribution to high-altitude adaptation. Mol Biol Evol (2013) 1.14
New-onset heart failure after permanent right ventricular apical pacing in patients with acquired high-grade atrioventricular block and normal left ventricular function. J Cardiovasc Electrophysiol (2007) 1.13
Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett (2009) 1.11
Vertically aligned carbon nanofiber architecture as a multifunctional 3-D neural electrical interface. IEEE Trans Biomed Eng (2007) 1.09
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood (2014) 1.09
[REPAIR OF ACUTE CLOSED ACHILLES TENDON RUPTURES BY CHANNEL-ASSISTED MINIMALLY INVASIVE REPAIR SYSTEM]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2015) 1.07
Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res (2007) 1.07
A novel calcium-binding site of von Willebrand factor A2 domain regulates its cleavage by ADAMTS13. Blood (2011) 1.06
Comparative transcriptional profiling and preliminary study on heterosis mechanism of super-hybrid rice. Mol Plant (2010) 1.05
A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer. Clin Cancer Res (2007) 1.02
Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol (2013) 1.02
Matrine inhibits proliferation and induces apoptosis of pancreatic cancer cells in vitro and in vivo. Biol Pharm Bull (2010) 1.01
Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother (2006) 1.01
Variation in carbon storage and its distribution by stand age and forest type in boreal and temperate forests in northeastern China. PLoS One (2013) 1.00
Field and long-term demonstration of a wide area quantum key distribution network. Opt Express (2014) 0.99
Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway. Cancer Chemother Pharmacol (2011) 0.99
Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol (2007) 0.99
Superior efficacy of tumor cell vaccines grown in physiologic oxygen. Clin Cancer Res (2010) 0.98
Effects of carbon monoxide releasing molecule-liberated CO on severe acute pancreatitis in rats. Cytokine (2009) 0.98
Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis. Clin Cancer Res (2008) 0.98
A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res (2009) 0.97
Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model. J Neurooncol (2007) 0.97
Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm (2006) 0.97
The deubiquitinating protein USP24 interacts with DDB2 and regulates DDB2 stability. Cell Cycle (2012) 0.97
Radiographic evaluation of selective anterior thoracolumbar or lumbar fusion for adolescent idiopathic scoliosis. Eur Spine J (2007) 0.97
Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology (2013) 0.96
Efficacy of nonviral gene transfer in the canine brain. J Neurosurg (2007) 0.95
Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother (2008) 0.95
Observed prevalence of congenital heart defects from a surveillance study in China. J Ultrasound Med (2011) 0.95
Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther (2010) 0.95
Miniaturized multiplex label-free electronic chip for rapid nucleic acid analysis based on carbon nanotube nanoelectrode arrays. Clin Chem (2004) 0.94
Improvement of tumor response by manipulation of tumor oxygenation during photodynamic therapy. Photochem Photobiol (2002) 0.94
Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother (2013) 0.94
Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents. Mol Cancer Ther (2012) 0.94
Risk of falls and fractures in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. Drugs Aging (2010) 0.94
Characterization of carbon nanofiber electrode arrays using electrochemical impedance spectroscopy: effect of scaling down electrode size. ACS Nano (2010) 0.94
Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm (2013) 0.93
Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses. Mol Ther (2013) 0.93
Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. J Pharm Pharm Sci (2006) 0.92
Glioma stem cells involved in tumor tissue remodeling in a xenograft model. J Neurosurg (2010) 0.92